文献速递肿瘤 PET/CT核素与放射性配体治疗

CAR-T治疗DLBCL患者的[18F]FDG PET-CT:治疗前后检查报告实用方法

[18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-09-04

该研究纳入48例接受CAR-T治疗的复发/难治性弥漫大B细胞淋巴瘤患者,共138次PET-CT扫描,旨在确定CAR-T治疗背景下PET-CT报告应关注的参数。结果显示治疗决策时SUVmax>17.1和输注时SUVmax>12.1与更短总生存相关,M1时Deauville评分>3及ΔSUVmax≤66%(对比决策时)可识别早期治疗失败。

要点

  • 治疗决策时SUVmax>17.1与更短总生存显著相关(HR 10.3,Pv<0.01)。
  • M1时Deauville评分>3者总生存显著缩短(中位7.9个月 vs 未达到,Pv<0.01)。
  • M1时ΔSUVmax≤66%(对比决策时SUVmax)预测更短总生存(Pv=0.02)。

核心结论

  • 治疗前SUVmax可能有助于CAR-T治疗的患者选择。
  • M1-PET-CT的Deauville评分和基于决策时SUVmax的ΔSUVmax可识别早期治疗失败。
  • 这些参数易于获取,应纳入PET-CT报告。

研究设计与样本

  • 回顾性纳入48例接受CAR-T治疗的复发/难治性弥漫大B细胞淋巴瘤患者,共138次PET-CT扫描(决策时30次、输注时42次、M1 44次、M3 22次)。
  • 计算所有扫描的SUVmax、TMTV和TLG,采用Deauville量表和ΔSUVmax方法评估反应,主要终点为总生存。
  • 中位随访时间自CAR-T输注起为12.8个月(IQR 6.4-16.0)。

主要发现

  • 单因素分析中,决策时SUVmax>17.1和输注时SUVmax>12.1与更短总生存相关(Pv<0.05)。
  • 多因素分析中,决策时SUVmax>17.1(HR 10.3;Pv<0.01)、LDH>450 U/l(HR 7.7;Pv<0.01)和ECOG评分>1(HR 5.5;Pv=0.04)与更短总生存显著相关。
  • 决策时和输注时PET-CT数据不能预测毒性。
  • M1-PET-CT中Deauville评分>3者总生存显著缩短(中位7.9个月 vs 未达到,Pv<0.01)。
  • M1-PET-CT的ΔSUVmax≤66%(对比决策时SUVmax)预测更短总生存(Pv=0.02),但对比输注时SUVmax无预测价值(Pv=0.38)。

关键数值与推荐

  • 决策时SUVmax>17.1(HR 10.3;Pv<0.01)、LDH>450 U/l(HR 7.7;Pv<0.01)、ECOG评分>1(HR 5.5;Pv=0.04)与更短总生存独立相关。
  • M1-PET-CT Deauville评分>3与更短总生存相关(中位7.9个月 vs 未达到,Pv<0.01)。
  • M1-PET-CT ΔSUVmax≤66%(对比决策时SUVmax)与更短总生存相关(Pv=0.02)。

临床怎么用

  • 在CAR-T治疗前的PET-CT报告中应关注并报告SUVmax,尤其是决策时SUVmax>17.1和输注时SUVmax>12.1。
  • M1-PET-CT报告应包含Deauville评分和基于决策时SUVmax计算的ΔSUVmax,以帮助早期识别治疗失败。
  • 决策时和输注时PET-CT参数不用于预测毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The introduction of CD19-specific chimeric antigen receptor T-cell therapy (CAR-T) for treatment of relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) gives hope to patients with otherwise dismal prognosis. Therapy outcomes, however, depend upon selection of patients and accurate early identification of non-responders. Patients treated with CAR-T usually undergo [18F]FDG PET-CT at time of decision (TD), time of CAR-T transfusion (TT), 1 month (M1), and 3 months (M3) post-therapy. The purpose of the current study was to identify the specific parameters that should be addressed when reporting PET-CT studies in the clinical setting of CAR-T therapy. METHODS: A total of 138 PET-CT scans (30 TD, 42 TT, 44 M1, 22 M3) of 48 patients treated with CAR-T were included. SUVmax, TMTV, and TLG were calculated in all scans. Response was assessed using the Deauville scale and ΔSUVmax method. Overall survival (OS) was the primary endpoint. Median follow-up was 12.8 (IQR 6.4-16.0) months from CAR-T infusion. RESULTS: In a univariate analysis, TD-SUVmax > 17.1 and TT-SUVmax > 12.1 were associated with shorter OS (Pv < 0.05). In a multivariate analysis, three factors were significantly associated with shorter OS: TD-SUVmax > 17.1 (HR 10.3; Pv < 0.01), LDH > 450 U/l (HR 7.7; Pv < 0.01), and ECOG score > 1 (HR 5.5; Pv = 0.04). Data from TD and TT PET-CT scans were not predictive of toxicity. On M1-PET-CT, patients with a Deauville score > 3 had significantly shorter OS (median 7.9 months, versus not reached, Pv < 0.01). ΔSUVmax ≤ 66% on M1-PET-CT predicted shorter OS when M1-SUVmax was compared to TD-SUVmax (Pv = 0.02) but not to TT-SUVmax (Pv = 0.38). CONCLUSION: Pre-treatment SUVmax may guide patient selection for CAR-T therapy. On M1-PET-CT, Deauville score and ΔSUVmax from TD may identify early therapy failure. These parameters are easy to obtain and should be included in the PET-CT report.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cohen D, Luttwak E, Beyar-Katz O, et al. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies. Eur J Nucl Med Mol Imaging. 2021. PMID: 34480603. doi:10.1007/s00259-021-05551-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。